“A ‘Start’ That Stands Out, Bringing in Talented Young Professionals — Qirui Group’s 2026 Campus Recruitment Concludes Successfully”
Category: News and Information
Release Date: 2025-12-31
Summary: Recently, Qirui Group’s 2026 campus recruitment campaign concluded successfully. Under the theme “A Remarkable Start, Unstoppable Success,” the group visited numerous universities across the country, engaging in enthusiastic exchanges with aspiring students who dream of making their mark in the pharmaceutical industry and collaboratively mapping out their career paths.
Recently, Qirui Group Class of 2026 The campus recruitment campaign has successfully come to a close. Under the theme “A Remarkable Start, an Unstoppable Momentum,” the Group visited numerous universities across the country, engaging in enthusiastic exchanges with aspiring students who dream of making their mark in the pharmaceutical industry and collaboratively mapping out their career paths.
As a high-tech enterprise deeply rooted in the life and health sector, Qirui Group has clearly showcased its strength and vision—spanning the entire industry value chain from original innovation to end-user services—at recruitment presentations held at numerous universities across China.
Entering Higher Education Institutions: Precisely Connecting with Future Talent
Qirui Group’s campus recruitment team has conducted extensive outreach in key cities including Beijing, Shanghai, Wuhan, and Nanjing, visiting more than ten top universities and research institutions such as Peking University, Tsinghua University, the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, China Pharmaceutical University, Huazhong University of Science and Technology, Wuhan University, and Nanjing University.

This campus recruitment drive has hosted more than 20 specialized information sessions and dual-selection fairs. Through in-depth company presentations, face-to-face exchanges with senior executives, alumni success stories, and on-site Q&A sessions, we engaged students in meaningful discussions on career planning, industry prospects, and job requirements. The dual-selection fairs were marked by a vibrant atmosphere, with long lines forming at the Group’s booth, as students’ enthusiasm and energy vividly showcased the dynamic strength of the next generation in the pharmaceutical sector.
Diverse roles to unleash professional talent
For this recruitment drive, the Group is offering positions across multiple functional areas, including R&D, manufacturing, corporate functions, and marketing, with a strong focus on candidates with backgrounds in pharmacy, chemistry, biology, medicine, management, and related disciplines. In addition, the Group has specially established a rotational management trainee program designed to provide high-potential students from diverse academic backgrounds with comprehensive hands-on experience and a fast-track development pathway.
Systematic empowerment, illuminating career prospects
Qirui Group will provide every new hire with a clear career development path, featuring customized “Qixing” training programs, a dual-track (management and technical) development pathway, and a comprehensive, end-to-end training system to help graduates quickly integrate and achieve sustained growth.
The 2025 campus recruitment campaign has temporarily come to a close, but Qirui Group remains committed to connecting with young talent. The Group maintains year-round internship and open recruitment programs, and looks forward to partnering with even more outstanding individuals.
Keywords: “A ‘Start’ That Stands Out, Bringing in Talented Young Professionals — Qirui Group’s 2026 Campus Recruitment Concludes Successfully”
Related News Centers
Academic Column
Development History
-
2019
Release time:2023-01-05
-
2018
Release time:2023-01-05
-
2017
Release time:2023-01-05
-
2014
Release time:2023-01-05
-
2013
Release time:2023-01-05
-
2012
Release time:2023-01-05
-
2011
Release time:2023-01-05
-
2010
Release time:2023-01-05
-
2009
Release time:2023-01-05
-
2008
Release time:2023-01-05
-
2007
Release time:2023-01-05
-
2006
Release time:2023-01-05
-
2005
Release time:2023-01-05
-
2004
Release time:2022-12-30
-
2003
Release time:2022-12-30
Branch office
News and Information
-
Qirui Group’s First Innovative Drug, MY008211A Tablets (Lanocapam Hydrochloride Tablets), Successfully Achieves the Primary Efficacy Endpoint in Phase III Clinical Trials
Release time:2026-02-25
-
Qirui Group’s First Innovative Drug Passes Both National Key Inspections on the First Attempt
Release time:2026-01-27
-
Three Employees of Qirui Pharmaceutical Awarded Jiangxia District’s Tangxun Lake Talent Recognition!
Release time:2026-01-15
-
“A ‘Start’ That Stands Out, Bringing in Talented Young Professionals — Qirui Group’s 2026 Campus Recruitment Concludes Successfully”
Release time:2025-12-31
-
Qirui Pharmaceutical’s Ganyining® Ademetionine Disulfonate for Injection Wins Bid in the 11th National Centralized Procurement Round
Release time:2025-11-11
-
Qirui Group Makes Its Debut at the 17th Bio-Industry Conference
Release time:2025-09-08
-
Empowering Your Journey, Illuminating the Path Ahead—Qirui Group’s 2025 New Graduate Onboarding Program Concludes Successfully
Release time:2025-07-23
-
Internationally Accredited! Qirui Technology Earns ACCA Recognized Employer Status
Release time:2025-07-08
-
Safeguarding the Source of Life and Fortifying the Quality Defense Line for Pharmaceutical Water — Professional Training on Purified Water Systems at Qirui Pharmaceutical
Release time:2025-06-05
-
Wuhan Qirui Technology Development Co., Ltd. Donates RMB 100 Million to Huazhong University of Science and Technology
Release time:2025-03-17
-
People-Oriented, Win-Win Future | Qirui Pharmaceutical Honored as “2024 China’s Top Employer”
Release time:2025-02-18
-
Empowering Party Building to Unite New Forces, Achieve Synergy, and Expand “Health”
Release time:2024-07-10
-
Qirui Group Makes Its Debut at CPHI China 2024
Release time:2024-06-28
-
Enhancing Competence Through Competition and Pursuing Development Through Quality: Qirui Pharmaceutical Successfully Holds Its 2024 Annual Quality Knowledge Competition
Release time:2024-06-28
-
Shining with the Light of Wisdom, Passing on the Torch of Scholarship — The Joint Master’s Thesis Defense Ceremony between Qirui Pharmaceutical and China Pharmaceutical University Concludes Successfully
Release time:2024-06-07
-
Academic Gala | The 8th International Forum on Drug-Induced Liver Injury Concludes Successfully; Ornithine Aspartate Recommended in the “Chinese Guidelines for Primary Care Diagnosis and Management of Drug-Induced Liver Injury (2024)”
Release time:2024-05-31
-
Qirui Pharmaceutical Awarded the “Wuhan May Day Labor Medal”
Release time:2024-05-13
-
Qirui Pharmaceutical Selected for Inclusion in the 2023 Jiangxia District List of Proposed Projects for District-Level Technology Transfer and Key R&D Initiatives
Release time:2024-04-12
-
“Made in Wuhan” Generic Drugs Added to the 2020 National Reimbursement Drug List
Release time:2021-03-05
-
Congratulatory Letter to Shandong Ruiyin Bioengineering Co., Ltd.
Release time:2021-02-01
-
Douyin Live Stream Coverage | Qirui’s 2020 Annual Work Summary and Awards Ceremony Held Successfully!
Release time:2021-01-28
-
First Public Notice of the Environmental Impact Assessment for the Demonstration Project on the Transformation and Construction of a Multi-Functional, Intelligent, Safe, Green, and High-End Active Pharmaceutical Ingredient Production Platform and Pilot-Scale Service Platform at Wuhan Zhongyou Pharmaceutical Co., Ltd.
Release time:2020-06-28
-
Decision on Commending the 2020 Pioneers in Epidemic Prevention Responsibility and Model Workers in Resuming Work and Production
Release time:2020-05-11
-
Notice of the Renewal of the Employee Care and Corporate Culture Development Committee
Release time:2020-04-27
Sunshine Avenue, Sunshine Third Road, Miaoshan Subdistrict, Economic Development Zone, Jiangxia District, Wuhan, Hubei Province
QR code
Copyright © Wuhan Qirui Pharmaceutical Co., Ltd. |Privacy Policy
Powered by www.300.cn
This website supports IPv6.